Last reviewed · How we verify
AN2690 Solution, 7.5%
AN2690 Solution, 7.5% is a drug that works by inhibiting the activity of the sodium channel Nav1.8.
AN2690 Solution, 7.5% is a drug that works by inhibiting the activity of the sodium channel Nav1.8. Used for Treatment of neuropathic pain.
At a glance
| Generic name | AN2690 Solution, 7.5% |
|---|---|
| Sponsor | Pfizer |
| Drug class | sodium channel blocker |
| Target | Nav1.8 |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 2 |
Mechanism of action
This inhibition is thought to reduce pain by blocking the transmission of pain signals to the brain. AN2690 Solution, 7.5% has been investigated for its potential to treat various types of pain, including neuropathic pain.
Approved indications
- Treatment of neuropathic pain
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- Cumulative Irritation Test (PHASE1)
- Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I) (PHASE2)
- Study of Different Doses of a Novel Treatment for Onychomycosis (PHASE2)
- Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail (PHASE2)
- Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail (PHASE2)
- Study of Different Doses of a Novel Treatment for Onychomycosis (PHASE2)
- Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |